On the 4 published Phase 1/2 #SARSCoV2 vaccine programs
(@moderna_tx @UniofOxford @Pfizer CanSino)
1. None have shown prevention of infections or disease; they show an antibody response, some T cell response, and preliminary safety. Can't be emphasized enough.
(@moderna_tx @UniofOxford @Pfizer CanSino)
1. None have shown prevention of infections or disease; they show an antibody response, some T cell response, and preliminary safety. Can't be emphasized enough.
2. We have no idea about durability. The virus is only ~8 months old!
3. Only 2 of these programs presented specific T-cell response data (perhaps a proxy for longer-lasting protection):
Pfizer/BioNTech program CD4+ in 34/36 patients, CD8+ 29/36 patients
Moderna mostly only CD4+
3. Only 2 of these programs presented specific T-cell response data (perhaps a proxy for longer-lasting protection):
Pfizer/BioNTech program CD4+ in 34/36 patients, CD8+ 29/36 patients
Moderna mostly only CD4+
References for T cell data
Pfizer/BioNTech
medrxiv.org/content/10.110…
Moderna nejm.org/doi/suppl/10.1…
Pfizer/BioNTech
medrxiv.org/content/10.110…
Moderna nejm.org/doi/suppl/10.1…
1 more point: Phase 1/2 vaccine trials aren't intended to show prevention of infection/ disease (thanks @bhalomanush suggestion to clarify). These important efforts are doing precisely what they are designed to do: test the immune response in people and get a sense about safety
